Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs. We are a well-known supplier of oncology drugs, surgical drugs, and interventional imaging solutions in China. Hengrui Pharma ranked 21st among the top 1,000 global pharma companies announced by the Torreya in 2020. Hengrui Pharma has been on the Pharma Exec’s annual listing of the top global pharmaceutical companies for the third consecutive year, rising from 47th in 2019 to 38th in 2021.

Innovation is the core of Hengrui’s development strategy. Hengrui’s R&D investment in recent years has accounted for about 17% of revenue. We spent 768 million USD (4.99 billion RMB) in R&D in 2020, which is nearly 18% of the 2020 revenue. We have built a large-scale, professional, and comprehensive innovative drug research staff of more than 4,500 people. Sixteen R&D centers were built around the world and several subsidiaries were established in the US, EU, Australia, and Japan. We have 8 innovative products marketed, more than 50 innovative candidates in the R&D stage, more than 20 innovative products under clinical development around the world. As of October 2021, 1275 patent applications have been submitted, with 346 patents granted in China and 463 patents granted worldwide, such as the US, EU, and Japan.

Hengrui has established manufacturing facilities all over the country and most of them conform with the USP, EUP, and JP standards. We have exported injections on a large scale to the US, EU, and Japan markets. Through our international partners, 21 formulation products were launched in the US, EU, and Japan to benefit more patients around the world.

Hengrui will continue its engagement in the innovation and development of treatments for various diseases spanning oncology, metabolic diseases, autoimmune diseases, cardiovascular diseases, and other therapeutic areas to benefit patients globally.